DUNDAS, ON, May 12 /CNW/ - Anne Tomalin, President of CanReg Inc., is
pleased to announce that Dayton T. Reardan, Ph.D., RAC has joined CanReg as
Executive Advisory Strategist to assist client firms with their US regulatory
needs. Dr. Reardan has held executive positions with small to medium sized
public and private biotechnology and pharmaceutical firms. During this time,
his focus has been on directing and managing regulatory affairs, most recently
with the US-based companies Orphan Medical Inc. and Eleos Inc.
Dr. Reardan has extensive experience in the arena of orphan drug
development, having participated in more than 15 orphan drug designations in
the United States and Europe resulting in 12 approved marketing indications
(US, Europe, Canada, Israel, Japan, South Africa, Australia, New Zealand). Six
of these were for new chemical entities with the FDA, including the many
supplemental label expansions, and their associative regulatory
investigational filings. Dr. Reardan has been twice awarded the FDA
Commissioner's Special Citation for his contributions to orphan drug
development and registration.
CanReg has supported the world-wide pharmaceutical, biotechnology and
device industry representing companies, large and small, with their FDA,
Health Canada, European and world-wide regulatory requirements. Dayton Reardan
can be reached at email@example.com or by calling CanReg at 1 866
About CanReg Inc.
CanReg is a company dedicated to strategic consulting and tactical
regulatory services in the United States, Canada, and Europe. More than 100
in-house consultants and staff support our pharmaceutical, biotechnology and
medical device clients in these markets, from investigational products through
registration and post-approval world-wide.
For further information:
For further information: Darrell Ethell, Executive Director, Business
Development, (905) 689-3980 extension 1242, firstname.lastname@example.org